First Author: S.Khochtali TUNISIA
Co Author(s): A. Invernizzi I. Ksiaa S. Zina F. Viola M. Khairallah
Back to previous
To report visual outcomes of intravitreal anti-vascular endothelial growth factors (anti-VEGF) in inflammatory choroidal neovascularization (CNV).
Two referral centres : Department of Ophthalmology, Fattouma Bourguiba University Hospital, Faculty of Medicine, University of Monastir, Monastir, Tunisia and Department of Clinical Sciences and Community Health, University of Milan, Ophthalmological Unit, IRCCS-Cà Granda Foundation - Ospedale Maggiore Policlinico, Milan, Italy.
Retrospective study of 43 eyes of 38 patients with CNV related to uveitis, treated with intravitreal injections of anti-VEGF, with or without systemic anti-inflammatory therapy. Patients were enrolled from two different referral centres.
Mean age was 35.5 years. Sex ratio was 0.27. Seventeen eyes (39.5%) of 17 patients (44.7%) had only anti-VEGF injections and 26 eyes (60.5%) of 21 patients (45.3%) had anti-VEGF injections associated with systemic anti-inflammatory therapy. Bevacizumab was injected in 36 eyes (83.7%), ranibizumab in 6 eyes (14%), and aflibercept in one eye (2.3%). Mean follow-up was 20.3 ± 19.2 months (range, 6-106 months). Mean visual acuity improved from 0.16 to 0.3 (p<10-3). Mean central macular thickness on optical coherence tomography decreased from 403.7 ± 121.9 to 293.7 ± 82.8 µm (p<10-3). Mean gain of vision was 2.9 lines. The mean number of injections was 2.5. There was no statistically significant difference between the whole group and the group of eyes that had bevacizumab injections with regard to final visual acuity, gain of vision and number of injections. There were no side effects related to the intravitreal injections of anti-VEGF.
CNV is a sight-threatening complication of uveitis. Intravitreal anti-VEGF seems to be an effective and safe treatment for inflammatory CNV when inflammation is controlled.